ClinicalTrials.gg

Program

Furosemide

Also written as “Furosemide 40 mg”, “SQIN-Furosemide” and “CLS006 (Furosemide) Topical Gel”.

Its studies are mostly in Heart Failure · Warts · Liver Cirrhosis · Pulmonary Arterial Hypertension · Diabetes Mellitus, led by 7 companies.

Furthest: phase 3, since Sep 3, 201415 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim70 open or runningphase 1since Sep 3, 2014Sep 3, 2014none ahead
Mannkind20 open or runningphase 2since Dec 9, 2014Dec 9, 2014none ahead
Maruho20 open or runningphase 3since Nov 21, 2016Dec 19, 2014none ahead
PT Bio Farma10 open or runningno phasesince Jul 18, 2021Jul 18, 2021none ahead
Sanofi10 open or runningphase 1since Oct 30, 2012Oct 30, 2012none ahead
SQ Innovation10 open or runningphase 1since Nov 18, 2025Nov 18, 2025none ahead
Sun Pharmaceutical Industries10 open or runningno phasesince Oct 22, 2008Oct 22, 2008none ahead

Also a collaborator on its studies: parexel, bdd-pharma-ltd, pt-pharma-metric-labs and cssi-life-sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Oct 22, 2008.

  1. Oct 30, 2012Sanofi's first study: phase 1 study in Renal InsufficiencyNew to SanofiSanofi · NCT01724788 · 12 enrolled · Canada
  2. Sep 3, 2014Boehringer Ingelheim's first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT02231931 · 24 enrolled · Germany
  3. Dec 9, 2014Mannkind's first study: phase 2 study in Heart FailureNew to MannkindMannkind · NCT02350725 · 10 enrolled · Netherlands
  4. Dec 19, 2014Maruho's first study: phase 2 study in Cutaneous WartsNew to MaruhoMaruho · NCT02333643 · 81 enrolled · Netherlands
  5. Oct 12, 2015Phase 1 study in HealthyBoehringer Ingelheim · NCT02574845 · 18 enrolled · Germany
  6. Aug 1, 2016Phase 1 study in HealthyBoehringer Ingelheim · NCT02854527 · 30 enrolled · Germany
  7. Nov 21, 2016Phase 3 study in Cutaneous Common WartsMaruho · NCT02971891 · 484 enrolled · United States
  8. Oct 6, 2017Phase 1 study in HealthyBoehringer Ingelheim · NCT03307252 · 45 enrolled · Germany
  9. Nov 7, 2019Phase 1 study in HealthyMannkind · NCT04161482 · 39 enrolled · United States
  10. Oct 15, 2020Phase 1 study in HealthyBoehringer Ingelheim · NCT04590937 · 15 enrolled · Germany
  11. Jul 18, 2021PT Bio Farma's first study: no phase study in Drug UseNew to PT Bio FarmaPT Bio Farma · NCT04982874 · 24 enrolled · Indonesia
  12. Feb 14, 2023No phase study in Liver CirrhosisBoehringer Ingelheim · NCT05741372 · 28 enrolled · Germany
  13. Jul 11, 2024Phase 1 study in HealthyBoehringer Ingelheim · NCT06504862 · 32 enrolled · Germany
  14. Nov 18, 2025SQ Innovation's first study: phase 1 study in HealthyNew to SQ InnovationSQ Innovation · NCT07269496 · 16 enrolled · United Kingdom

TargetBeta

SLC12A1 →read by rule
“Sodium-(potassium)-chloride cotransporter 2 inhibitor”ChEMBL 37, by rule

Other programs on SLC12A1

ProgramCompanyFurthest phaseStudies
Torsemiderulesarfez-pharmaceuticals-incphase 413

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07269496Healthy · United Kingdom1CompletedSQ InnovationMar 9, 202616
NCT06504862Healthy · Germany1CompletedBoehringer IngelheimOct 3, 202432
NCT05741372Liver Cirrhosis · Germany–CompletedBoehringer IngelheimDec 18, 202428
NCT04982874Drug Use · Indonesia–CompletedPT Bio FarmaJan 17, 202024
NCT04590937Healthy · Germany1CompletedBoehringer IngelheimJan 11, 202115
NCT04161482Healthy · United States1CompletedMannkindJun 24, 202039
NCT03307252Healthy · Germany1CompletedBoehringer IngelheimMay 2, 201845
NCT02971891Cutaneous Common Warts · United States3CompletedMaruhoApr 16, 2018484
NCT02854527Healthy · Germany1CompletedBoehringer IngelheimNov 11, 201630
NCT02574845Healthy · Germany1CompletedBoehringer IngelheimDec 9, 201518
NCT02333643Cutaneous Warts · Netherlands2CompletedMaruhoAug 201581
NCT02350725Heart Failure · Netherlands2CompletedMannkindJun 201510
NCT02231931Healthy · Germany1CompletedBoehringer IngelheimJan 1, 201524
NCT01724788Renal Insufficiency · Canada1CompletedSanofiJan 201312
NCT00778180Healthy · United States–CompletedSun Pharmaceutical IndustriesOct 200544

How it is read

Names in the registry

  • “Furosemide”, 16 entries
  • “Furosemide 40 mg”, 2 entries
  • “SQIN-Furosemide”, 1 entry
  • “CLS006 (Furosemide) Topical Gel”, 1 entry
  • “Lasix®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.